18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

  • STATUS
    Recruiting
  • participants needed
    400
  • sponsor
    VA Greater Los Angeles Healthcare System
Send
Updated on 19 February 2024
See if I qualify
ct scan
adenocarcinoma
positron emission tomography
definitive treatment
pet/ct scan
prostatectomy
external beam radiation therapy
conventional imaging
salvage therapy
adenocarcinoma of prostate
metastatic prostate cancer
prostate cancer metastatic

Summary

The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans.

In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires and corresponding changes in management will be analyzed. The scan will be used to see how the disease has spread. Both the treatment strategies and probable disease outcomes as relevant to clinical endpoints will be assessed. This study is open to Veterans only.

Details
Condition Malignant neoplasm of prostate, Prostatic disorder
Age 18years - 100years
Treatment 18F-DCFPyL
Clinical Study IdentifierNCT04390880
SponsorVA Greater Los Angeles Healthcare System
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

b'Participants who fulfill criteria for initial staging or restaging as outlined below:'
b'Initial treatment strategy decisions (initial staging)'
b'All participants with histologically proven prostate cancer or strong suspicion'
b'of prostate adenocarcinoma based on very high PSA levels (>50 ng/mL) who require'
b'an initial treatment/management decision who may be candidate for any of the'
b'following strategies:'
b'A) Surgery B) External radiation therapy (RT) C) Other focal therapies D)'
b'Systemic medical treatment E) Watchful waiting'
b'Assessment for Subsequent treatment strategy (restaging), any of the following:'
b'A) Participants with biochemical recurrence who are potential candidates for any salvage'
b'treatment. Biochemical recurrence is defined by rising PSA after definitive therapy with'
b'prostatectomy or radiation therapy, as any of the following:'
b'Post radical prostatectomy (RP): PSA equals to or greater than 0.2 ng/mL measured more'
b'than 6 weeks after RP'
b'Post-radiation therapy : Nadir + greater than or equal to 2 ng/mL rise in PSA B)'
b'Participants with known prostate cancer who undergo restaging because of new symptoms'
b'C) Participants with known metastatic prostate cancer who undergo restaging because of'
b'rising PSA with negative or inconclusive conventional imaging D) Participants with'
b'known prostate cancer who are treated medically or with RLT in whom response to'
b'treatment is assessed'
b'Capability to provide written informed consent'
b'Able to remain still for duration of each imaging procedure (about 30 minutes) *'
b'Participants may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed'
b'for subsequent management decision.'

Exclusion Criteria

b'Less than 18 years-old at the time of radiotracer administration'
b'Inability to complete the needed investigational and standard-of-care imaging'
b'examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)'
b'Any additional medical condition, serious concurrent illness, or other extenuating'
b'circumstance that, in the opinion of the Investigator, may significantly interfere'
b'with study compliance.'
b'Inability to provide written informed consent'
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

ct scan
adenocarcinoma
positron emission tomography
definitive treatment
pet/ct scan
prostatectomy
external beam radiation therapy
conventional imaging
salvage therapy
adenocarcinoma of prostate
metastatic prostate cancer
prostate cancer metastatic

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.